Evidence map›Paper›PMID 21223573›Full record

ArticleBMC biotechnology2011

A suicide gene approach using the human pro-apoptotic protein tBid inhibits HIV-1 replication.

Peter M Huelsmann, Andreas D Hofmann, Stefanie A Knoepfel, Jasmin Popp, Pia Rauch, Francesca Di Giallonardo, Christina Danke, Eva Gueckel, Axel Schambach, Horst Wolff and 2 more

Open access · goldAbstract read
In one paragraph

Article in BMC biotechnology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Prospects for treatment of latent HIV.Clinical pharmacology and therapeutics · 2013
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 2 countries.

Peter M HuelsmannUniversity of Erlangen-Nuremberg, Institute of Clinical and Molecular Virology, Erlangen, Germany.
Andreas D Hofmann
Stefanie A Knoepfel
Jasmin Popp
Pia Rauch
Francesca Di Giallonardo
Christina Danke
Eva Gueckel
Axel Schambach
Horst Wolff
Karin J Metzner
Christian Berens
Friedrich-Alexander-Universität Erlangen-Nürnberg · DEHelmholtz Zentrum München · DEMedizinische Hochschule Hannover · DEUniversity of Zurich · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundRegulated expression of suicide genes is a powerful tool to eliminate specific subsets of cells and will find widespread usage in both basic and applied science. A promising example is the specific elimination of human immunodeficiency virus type 1 (HIV-1) infected cells by LTR-driven suicide genes. The success of this approach, however, depends on a fast and effective suicide gene, which is expressed exclusively in HIV-1 infected cells. These preconditions have not yet been completely fulfilled and, thus, success of suicide approaches has been limited so far. We tested truncated Bid (tBid), a human pro-apoptotic protein that induces apoptosis very rapidly and efficiently, as suicide gene for gene therapy against HIV-1 infection.

resultsWhen tBid was introduced into the HIV-1 LTR-based, Tat- and Rev-dependent transgene expression vector pLRed(INS)2R, very efficient induction of apoptosis was observed within 24 hours, but only in the presence of both HIV-1 regulatory proteins Tat and Rev. Induction of apoptosis was not observed in their absence. Cells containing this vector rapidly died when transfected with plasmids containing full-length viral genomic DNA, completely eliminating the chance for HIV-1 replication. Viral replication was also strongly reduced when cells were infected with HIV-1 particles.

conclusionsThis suicide vector has the potential to establish a safe and effective gene therapy approach to exclusively eliminate HIV-1 infected cells before infectious virus particles are released.

Indexed as

Genes, Transgenic, SuicideBH3 Interacting Domain Death Agonist ProteinCloning, MolecularFlow CytometryGenetic VectorsHeLa CellsHIV-1Humansrev Gene Products, Human Immunodeficiency Virustat Gene Products, Human Immunodeficiency VirusVirus ReplicationBH3 Interacting Domain Death Agonist Proteinrev Gene Products, Human Immunodeficiency Virusrev protein, Human Immunodeficiency Virus-1tat Gene Products, Human Immunodeficiency Virus

Identifiers

PMID21223573
PMCPMC3224247
OpenAlexW2012833208

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.